CDP-diacylglycerol synthase 2 mRNA (CDS2 mRNA)

CDP-diacylglycerol synthase 2 (CDS2) mRNA encodes an integral membrane protein of the endoplasmic reticulum that catalyzes the conversion of phosphatidic acid to CDP-diacylglycerol, a rate-limiting step in the phosphoinositide (PI) cycle (UniProt: O95674). This cycle is essential for the synthesis of phosphatidylinositol and its phosphorylated derivatives, such as PIP2 and PIP3, which mediate critical cell signaling pathways. In oncology, CDS2 mRNA has emerged as a significant therapeutic target due to its synthetic lethal relationship with PTEN deficiency; PTEN-null cancer cells exhibit a unique dependency on CDS2-mediated PI recycling to maintain oncogenic signaling (PubMed: 25103333). Targeting the mRNA transcript via RNA interference or antisense technologies allows for the selective depletion of the enzyme, effectively starving PTEN-deficient tumors of necessary lipid precursors while sparing normal cells that can utilize alternative pathways. Additionally, CDS2 plays a vital role in vascular development by modulating VEGF signaling, suggesting its potential utility in treating angiogenesis-related disorders (PubMed: 28714926). Current therapeutic strategies are primarily focused on nucleic acid-based inhibitors, which are undergoing preclinical evaluation for their ability to induce apoptosis in susceptible tumor types.

Other names

CDP-diglyceride synthetase 2 mRNACDP-DAG synthase 2 mRNACDS2 transcript

RNA interference (RNAi) or antisense-mediated degradation of mRNA transcripts to prevent the translation of the CDP-diacylglycerol synthase 2 enzyme, thereby depleting the cellular pool of CDP-diacylglycerol (PubMed: 25103333).